Horizon scanning of new and emerging medical technology in Australia: Its relevance to Medical Services Advisory Committee health technology assessments and public funding

O'Malley, Sue P.; Jordan, Ernest

doi:10.1017/s0266462309990031

Cited by 18 publications

(22 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HealthPACT is both a sub-committee of MSAC and a working group under an AHMAC sub-committee. In addition, HealthPACT conducts horizon scanning to alert policy makers of emerging technologies [7,8]. Second, technology assessments are usually undertaken by a third party independent contracted evaluator.…”

Section: Introductionmentioning

confidence: 99%

Introduction and uptake of new medical technologies in the Australian health care system: A qualitative study

et al. 2011

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Introduction and uptake of new medical technologies in the Australian health care system: A qualitative study

et al. 2011

View full text Add to dashboard Cite

“…However, HSSs may also contribute to support key decisions made by the manufacturers during the product development process. Although experiences have been reported mainly on diagnostics and devices, 27 – 29 HSSs may help the drug developers to anticipate possible barriers to the downstream market access decision and to proactively work to overcome those by shaping the market and engaging stakeholders and key opinion leaders.…”

Section: Resultsmentioning

confidence: 99%

The role of health technology assessment bodies in shaping drug development

Ciani¹,

Jommi²

2014

DDDT

View full text Add to dashboard Cite

The use of health technology assessment (HTA) to inform policy-making is established in most developed countries. Compared to licensing agencies, HTA agencies have different interests and, therefore, different evidence requirements. Criteria for coverage or reimbursement decisions on pharmaceutical compounds vary; however, it is common to include, as part of the HTA, a comparative effectiveness evaluation. This type of clinical data might go beyond that required for market authorization, thus creating an additional evidence gap between the regulatory and the reimbursement submission. The relevance of submissions to HTA agencies is consistently increasing in a pharmaceutical company’s perspective, as market prospects are strongly influenced by third-party payers’ coverage. In this study, we aim to describe current HTA activities with a potential impact throughout the drug development process of pharmaceuticals, with a comparative emphasis on the systems in place in Italy and in the UK. Based on an extensive literature and website review, we identified three major classes of HTA activities, beyond mainstream HTA, with the potential to influence the drug development program: 1) horizon scanning and early HTA; 2) bipartite and tripartite early dialogue between manufacturers, regulators, and HTA assessors; and 3) managed market entry agreements. From early stages of clinical research up to postauthorization studies, there is a trend toward increased collaboration between parties, anticipation of market access evidence collection, and postmarketing risk-sharing. Heterogeneity of HTA practices increases the complexity of the market access environment. Overall, there are signals that market access departments are gaining importance in the pharmaceutical companies, but there is still a lack of evidence and reporting on how the increasing relevance of HTA has reshaped the way clinical development is designed and managed.

show abstract

“…For a new medical procedure to be listed on the Australian Medicare Benefits Schedule (MBS), an application must be made to MSAC for an HTA. Almost without exception, the need for an MSAC HTA is identified by the application sponsor rather than by the horizon scanning process that was introduced in 2004 with the aim of identifying new and emerging technology 5 . All medical devices associated with the new procedure require Therapeutic Goods Administration (TGA) registration before the application for the procedure can be lodged with MSAC.…”

Section: Current Health Technology Assessment Processmentioning

confidence: 99%

Issues facing the Australian Health Technology Assessment Review of medical technology funding

O'Malley¹

2010

Medical Journal of Australia

View full text Add to dashboard Cite

The Australian Health Technology Assessment Review has the potential to have a major effect on the availability of new medical technology and the listing of associated medical procedures on the Medicare Benefits Schedule. Despite this, only about 15% of submissions to the Review came from “medical associations”. Pharmaceutical and medical technologies are inherently different, and there are a number of difficulties associated with evaluating medical technology using the same process and evidence levels as those used for pharmaceuticals. The current sequential and lengthy processing of new medical technology and procedures is delaying access to beneficial medical technology and could be substantially reduced. There is currently no effective funding process for medical technology classified as capital equipment or consumables and disposables. This has created a perverse incentive in favour of using funded implantable prostheses based on access to funding rather than superior clinical effectiveness. The existing horizon scanning process could be better used to not only identify all potentially cost‐effective new and emerging medical technology and procedures as early as possible, but also to identify gaps in the evidence.

show abstract

Horizon scanning of new and emerging medical technology in Australia: Its relevance to Medical Services Advisory Committee health technology assessments and public funding

Cited by 18 publications

References 3 publications

Introduction and uptake of new medical technologies in the Australian health care system: A qualitative study

Introduction and uptake of new medical technologies in the Australian health care system: A qualitative study

The role of health technology assessment bodies in shaping drug development

Issues facing the Australian Health Technology Assessment Review of medical technology funding

Contact Info

Product

Resources

About